| Bioactivity | ATAC21, a linker-immune-stimulatory compound that can be formed by conjugating a noncleavable maleimide-PEG4 linker containing a succinimide group with an immune- stimulatory compound. ATAC21 can be combined with SBT-040 (anti-CD40 antibody) to form a conjugate[1]. |
| Invitro | 一种重组双特异性抗体，包括：a)靶抗原结合结构域，其中所述靶抗原结合结构域特异性结合肿瘤相关抗原； b)效应抗原结合结构域，其中效应抗原结合结构域特异性结合抗原呈递细胞上的抗原，并且其中抗原是抗原呈递细胞上的分子； c) 包含 Fc 的结构域； d)通过连接子连接到重组双特异性抗体上的免疫刺激化合物； 其中与重组双特异性抗体结合抗原呈递细胞上的抗原时相比，当重组双特异性抗体结合肿瘤相关抗原和抗原呈递细胞上的抗原时，重组双特异性抗体诱导更大的免疫细胞活化，但是不是肿瘤相关抗原[1]。 |
| Name | ATAC21 |
| CAS | 2101204-23-1 |
| Formula | C38H50N12O21P2 |
| Molar Mass | 1072.82 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
ATAC21
CAS: 2101204-23-1 F: C38H50N12O21P2 W: 1072.82
ATAC21, a linker-immune-stimulatory compound that can be formed by conjugating a noncleavable maleimide-PEG4 linker cont
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.